Soleno Therapeutics responds to short seller’s Prader-Willi drug safety claims

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

I respect the investigative skills and short-selling prowess of Kir Kahlon, the founder and chief investment officer at Scorpion Capital, but I think he’s off base with his most recent target: Soleno Therapeutics. 

Last week, Kahlon disclosed a short position in Soleno in conjunction with the release of a 415-page research report that, in bombastic language, leveled serious safety allegations against Vykat XR, the company’s recently approved treatment for Prader-Willi syndrome, a rare genetic disease that causes an insatiable desire to eat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In